Abstract
Proliferative vitreoretinopathy (PVR) can occur in eyes with rhegmatogenous retinal detachment (RRD) or after RRD surgery, and it is the most common cause of failure of this surgery, accounting for about 75% of all primary failures. Complex biological pathways induce PVR development, with growth factors and cytokines from the vitreous and from the serum (as a result of the breakdown of the blood-retinal barrier) stimulating RPE and Muller cells transformation and proliferation, and membrane formation and contraction.
Identification of pre-operative risk factors, recognition of the early signs of PVR, use of adequate surgical techniques and of pharmacological therapy can reduce the PRV incidence.
Steroids can influence the inflammatory and proliferative components of PVR, by reducing the breakdown of the blood-retinal barrier, and the proliferation of Müller cell and of RPE cells. Some new formulation of intravitreal steroids are promising tool for the prevention of the PVR formation in eyes treated by vitreoretinal surgery.
Keywords: Intravitreal steroids, prevention, proliferative vitreoretinopathy, retinal detachment.
Current Pharmaceutical Design
Title:Intravitreal Steroids for the Prevention of PVR After Surgery for Retinal Detachment
Volume: 21 Issue: 32
Author(s): Caterina Gagliano, Mario D. Toro, Teresio Avitabile, Santo Stella and Maurizio G. Uva
Affiliation:
Keywords: Intravitreal steroids, prevention, proliferative vitreoretinopathy, retinal detachment.
Abstract: Proliferative vitreoretinopathy (PVR) can occur in eyes with rhegmatogenous retinal detachment (RRD) or after RRD surgery, and it is the most common cause of failure of this surgery, accounting for about 75% of all primary failures. Complex biological pathways induce PVR development, with growth factors and cytokines from the vitreous and from the serum (as a result of the breakdown of the blood-retinal barrier) stimulating RPE and Muller cells transformation and proliferation, and membrane formation and contraction.
Identification of pre-operative risk factors, recognition of the early signs of PVR, use of adequate surgical techniques and of pharmacological therapy can reduce the PRV incidence.
Steroids can influence the inflammatory and proliferative components of PVR, by reducing the breakdown of the blood-retinal barrier, and the proliferation of Müller cell and of RPE cells. Some new formulation of intravitreal steroids are promising tool for the prevention of the PVR formation in eyes treated by vitreoretinal surgery.
Export Options
About this article
Cite this article as:
Gagliano Caterina, Toro D. Mario, Avitabile Teresio, Stella Santo and Uva G. Maurizio, Intravitreal Steroids for the Prevention of PVR After Surgery for Retinal Detachment, Current Pharmaceutical Design 2015; 21 (32) . https://dx.doi.org/10.2174/1381612821666150909100212
DOI https://dx.doi.org/10.2174/1381612821666150909100212 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of microRNAs in the Development of Type 2 Diabetes Complications
Current Pharmaceutical Design Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets Involvement of Coagulation and Hemostasis in Inflammatory Bowel Diseases
Current Vascular Pharmacology Erythropoietin and Oxidative Stress
Current Neurovascular Research Proliferative Retinopathies: Animal Models and Therapeutic Opportunities
Current Neurovascular Research Intravitreal Inserts of Steroids to Treat Diabetic Macular Edema
Current Diabetes Reviews AMPK as a New Attractive Therapeutic Target for Disease Prevention: The Role of Dietary Compounds AMPK and Disease Prevention
Current Drug Targets Enhanced Antioxidant and Protective Activities on Retinal Ganglion Cells of Carotenoids-Overexpressing Transgenic Carrot
Current Drug Targets Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design An Update on Drug Interactions with the Herbal Medicine Ginkgo biloba
Current Drug Metabolism Insights into the Platelet Releasate
Current Pharmaceutical Design Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma
Mini-Reviews in Medicinal Chemistry In Situ Gels Based Drug Delivery Systems
Current Drug Therapy Ocular Complications of Drugs Used in Rheumatic Disease
Current Rheumatology Reviews Central Retinal Vein Occlusion: Current Therapeutic Approach
Vascular Disease Prevention (Discontinued) Drug Delivery Systems for Ophthalmic Administration of Antiinflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Redox mechanisms in pathological angiogenesis in the retina: roles for NADPH oxidase
Current Pharmaceutical Design Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Pharmacogenomics of Open-Angle Glaucoma
Current Pharmacogenomics and Personalized Medicine Endothelial Dysfunction and Atherosclerosis: Focus on Novel Therapeutic Approaches
Recent Patents on Cardiovascular Drug Discovery